Page 89 - Read Online

Page 8 of 8 Pazgan-Simon. Hepatoma Res 2020;6:17 I http://dx.doi.org/10.20517/2394-5079.2019.52

infection. Hepatology 2020;71:686-721.
9. Butt AS, Sharif F, Abid S, Impact of direct acting antivirals on occurence and reccurence of hepatocellular carcinoma: Biologically
plausible or an epiphenomenon? World J Hepatol 2018;10:267-76.
10. Kobzial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic
patients with sustained virologic responce following interfeon - free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
11. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gstroenterology 2017;153:996-1005.e1.
12. Sinagl AG, Lim JK, Knawal F. AGA clinical practice update on interaction between oral direct- acting antivirals for chronic hepatitis
C and hepatocellular carcinoma: expert review. Gastoenterology 2019;145:2149-57.
13. Ioannou GN, Feld JJ. What are the benefits of a sustained virologic responce to direct-acting antiviral therapy for hepatitis C virus
infection? Gastroenterology 2019;156:446-60.e2.
14. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al. Effect of interferon-based and -free therapy on early occurence and
recurrence of hepatocellular carcinoma in chronić hepatitis C. J Hepatol 2017;67:933-9.
15. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic
patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.
16. Singal AG, Rich NE, Metha N, Branch A, Pillai A, et al. Direct-acting antiviral therapy not associated with recurrence of
hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156:1683-92.e1.